Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Neurobiol Aging. 2015 Oct 19;37:26–37. doi: 10.1016/j.neurobiolaging.2015.09.018

Table 6.

Drug trial enrichment using brain amyloid load at the screening visit

Group Amyloid+
Amyloid−
p
n Mean (SD) n80 (CI) n Mean (SD) n80 (CI)
CN 47 0.95 (0.80) 180 (103, 496) 103 0.74 (0.75) 257 (167, 473) 0.189
EMCI 67 1.26 (1.05) 174 (113, 288)   70 0.63 (0.81) 421 (240, 857) 0.012
LMCI 88 1.84 (1.24) 114 (81, 169)   40 0.82 (0.91) 309 (171, 701) 0.005
AD 68 2.37 (1.26)   71 (49, 111)     8 1.29 (1.27) 243 (117, 751) 0.061

Mean percentage of tissue atrophy (SD) and n80 (95% CI) for statistically defined region of interest numerical summaries are derived in CN, EMCI, LMCI, and AD groups over 12 months, amyloid+ [BL_SUVR_Summary ≥ 1.11] and amyloid− [BL_SUVR_Summary < 1.11]. n indicates the number of participants in the analysis. p Values estimate the evidence that the true 12-month n80 in amyloid− group is equal to or greater than that of the amyloid+ group (p < 0.05 marked in bold font).

Key: AD, Alzheimer’s disease; CI, confidence interval; CN, healthy controls; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; SD, standard deviation.